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Background: Escherichia coli O25b-B2-ST131 are considered virulent extra-intestinal pathogens causing serious
clinical complications such as urinary tract infection and bacteraemia. Our main objectives in this study were to
characterise the multi-drug resistant (MDR) isolates of this lineage in Kuwait, and to demonstrate whether reduced
susceptibility is spread clonally.
Results: A subset of 83 (10%) non-duplicate and non-selective E. coli O25b-B2-ST131 out of 832 MDR E. coli was
identified and collected. Minimum inhibitory concentrations of the isolates were determined and pulsed-field gel
electrophoresis was used for typing.
The majority (95.2%) of the 83 E. coli O25b-B2-ST131 harboured at least one bla gene with blaCTX-M-15 being the
most prevalent. blaCTX-M-2 was present in one isolate. Also one isolate harboured blaCTX-M-56, qnrB1 and blaCMY-2
genes and carried IncF1 plasmids of about 97 kb and160 kb. qnrB and qnrS were found in 8 other blaCTX-M-15
containing isolates. The blaNDM, blaIMP, blaVIM and qnrA were not detected, however, the blaOXA-48 was present in
two (2.4%).
Conclusions: The majority of isolates harbouring qnr genes demonstrated relatedness (≥85%) by PFGE. However,
the diversity in PFGE profiles for the other MDR isolates reflected the changes in population genetics of E. coli
O25b-B2-ST131. We identified for the first time the appearance of blaCTX-M-2 in the Middle East and blaCTX-M-56
outside the Latin American countries. The isolate harbouring blaCTX-M-56 also contained qnrB1 and blaCMY-2 genes
and carried IncF1 plasmids. The appearance of a highly virulent E. coli O25b-ST131 that is resistant to penicillins,
most cephalosproins, β-lactamase inhibitors as well as fluoroquinolones is a cause for concern.
Keywords: Escherichia coli ST131, Pulsed-field gel electrophoresis, Extended spectrum beta-lactamases, qnrBBackground
Escherichia coli belonging to the phylogenic group B2, sero-
type O25b:H4 and Multi-Locus Sequence Type (ST) 131
(E. coli O25b-B2-ST131), producing extended-spectrum
β-lactamase (ESBL) is regarded as a major pandemic clone
in community and hospitals causing serious clinical infec-
tions such as urinary tract infections and bacteraemia [1].
It has been shown that E. coli O25b-B2-ST131 exhibits a
high virulence score compared to other lineages [2] and
is capable of acquiring antibiotic resistance by different* Correspondence: leila@hsc.edu.kw
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unless otherwise stated.mechanisms [3-6]. The fact that E. coli O25b-B2-ST131 is
able to exhibit antibiotic resistance means that the clinical
environment within a hospital or community may actively
select certain resistant strains [7] making the treatment of
these infections increasingly difficult. Analysis by pulsed
field gel electrophoresis (PFGE) has identified a high degree
of genetic diversity among the E. coli O25b-B2-ST131 iso-
lates; however, some types appear to be more common in
certain regions than others [4].
An important cause of resistance in E. coli O25b-B2-
ST131 is the production of β-lactamase enzymes. Some of
the most prevalent of these are CTX-M-like enzymes as
well as other types specifically TEM-1, TEM-24, SHV-12
and the plasmid-mediated AmpC CMY-2 [8-10]. Further-
more, CTX-M-15 producing strains often co-produceis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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modifying enzyme that is responsible for reduced sus-
ceptibility both to the aminoglycosides and to some
fluoroquinolones expressed by aac(6’)-Ib-cr genes [5,6].
Fluoroquinolone (FQ) resistance in Enterobacteriaceae
is usually caused by mutations in the chromosomal
genes coding for type II topoisomerases and changes in
the expression of efflux pumps and porins. The rise of
plasmid-mediated FQ resistance protein Qnr [11] has
caused concern in antimicrobial treatment of Enterobacte-
riaceae whereby carbapenems are considered the best
therapeutic option [12]. Nevertheless some Enterobac-
tericeae can produce clinically important carbapene-
mases; the Ambler class B metallo-β-lactamases (NDM,
IMP, VIM), the class A enzymes (KPC) and the class D
oxacillinase enzymes (OXA-48). Until recently E. coli was
less often affiliated with carbapenemases than Klebsiella
pneumoniae, however, the recent emergence of blaNDM
gene (New Delhi metallo-β-lactamase) on plasmids in
E.coli ST131strains has caused concern [13-15]. The
NDM-like enzymes have been identified in different re-
gions [16] including in clinical K. pneumoniae isolates
from Kuwait [17] and Oman [18] in the Middle East.
The blaOXA-48 carbapenemase is mainly associated
with the Tn1999-like transposon inserted into a single
62-kb IncL/M-type plasmid [19]. It has been detected in
sporadic cases; E. coli ST1196 (also containing resistance
genes: blaCMY-2, blaSHV-12 and blaTEM-1) and E. coli ST1431
(containing β-lactamase genes: blaCTX-M-1, blaOXA-2 and
blaTEM-1) isolated from pet dogs [20] and E. coli (containing
blaCTX-M-15 and blaTEM-1 genes) isolated from a Belgian pa-
tient with ventilator-associated pneumonia travelling back
from Egypt [21].
To date reports from the Middle East has been fo-
cused on the sporadic and selective E. coli O25b-
B2-ST131 cases [22] and a comprehensive study on the
epidemiology of this lineage was lacking. Therefore we
aimed to address this issue by systematically characteris-
ing the multi-drug resistant (MDR) isolates of E. coli
O25b-B2-ST131 recovered from patients in order to use




A survey of Extended Spectrum β-lactamase (ESBL)-
producing Enterobacteriaceae was undertaken from
January 2010 to December 2012. A subset of 832 MDR
E. coli strains was collected from the microbiology la-
boratories of three major hospitals that serve the six
governorates of Kuwait. All the three hospitals are ter-
tiary health care providers with bed capacities of 300 for
Ahmadi, 500 for Amiri and 600 for Yiaco-Adan. The
average number of specimens processed each day variesfrom 500 to 700 which includes samples from out-
patient and in-patient specialists units. 832 original iso-
lates represent a subset of the isolates submitted to the
clinical diagnostic laboratories of these centres.
Each patient was included only once in this study. A
database was created based on the patient’s records that
contained information; such as age, sex, hospital, location
of care on each site, type of specimen and date of sam-
pling. Specimens were processed by clinical staff members
of the diagnostic laboratories using standard protocols.
Cultures were performed on blood agar, MacConkey,
Cystine lactose electrolyte deficient agar (CLED) and incu-
bated aerobically and anaerobically as required. All iso-
lates were identified at the species level based on colony
morphology, biochemical analysis and by using Vitek2
(Vitek AMS; bioMérieux Vitek Systems Inc., Hazelwood,
MO, USA). The isolates were stored in 10% skim milk and
at -70°C.
To confirm the phylogenic grouping of E. coli O25b-
B2-ST131, PCR amplification of the pabB, trpA, chuA,
yjaA genes [23] and DNA fragment of TSPE4.C2 were
carried out as described before [24]. The products were
sequenced from both directions and analysed.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was determined by
automated broth microdilution method (Vitek2) (Vitek
AMS; BioMérieux Vitek Systems Inc., Durham, NC, USA)
and the results were analysed according to the Clinical
and Laboratory Standards Institute, CLSI (2012) guide-
lines [25]. The antibiotics tested in this study were:
Amikacin, amoxicillin/clavulanic acid, amp/sulbactam,
ampicillin, cefazolin, cefepime, cefotaxime, ceftazidime,
ceftriaxone, cefuroxime, cefoxitin, cefpodoxime, cepha-
lothin, ceftriazone, ciprofloxacin, gentamicin, imipenem,
meropenem, levofloxacin, nitrofurantoin, norfloxacin,
tetracycline, tobramycin, trimethoprim/sulfamethoxa-
zole, piperacillin/tazobactam, pipercillin and tigecycline.
ESBL production was confirmed by vitek2 analyzer
and disk diffusion. Minimum inhibitory concentration
(MICs) of quinolones, fluoro-quinolones and β-lactams
including carbapenems were determined using the E-test
method (CLSI 2012) [25]. Isolates that showed resistance
to at least three classes of antibiotics were considered as
MDR. Isolates that were detected as resistant to cefoxitin
were further investigated for the presence of an ampC
β-lactamase by using multiplex PCR [8,26].
Double-disc synergy method
ESBLs were detected as previously described [27] using
the disc approximation and double-disc synergy methods
and confirmed with cefotaxime and ceftazidime E-test
ESBL strips (AB Biodisk, Biomerieux-diagnostics, Durham,
NC, USA). For the disc approximation test, clavulanate
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disc was used to test for synergy with cefotaxime, cef-
tazidime, cefuroxime, cefepime and cefixime (Oxoid) as
described previously [28]. For the double-disc synergy
test, a ceftazidime disc (30 μg) was placed 30 mm away
from a disc containing amoxicillin–clavulanate (60/10 μg).
ESBL production was considered positive when an
enhanced zone of inhibition was visible between the
β-lactam and β-lactamase inhibitor-containing discs.
For the E-test, ESBL strips containing ceftazidime and
ceftazidime–clavulanate and strips containing cefotax-
ime and cefotaxime–clavulanate were used to determine
the MIC ratio according to the manufacturer’s instruc-
tions (AB Biodisk, Biomerieux-diagnostics, Durham,
NC, USA). Cultures were incubated aerobically at 37°C
for 18–24 h. CTX-M-15 β-lactamase enzyme displays a
catalytic activity toward ceftazidime.Modified Hodge test
The test inoculum (0.5 McFarland turbidity) was spread
onto Mueller-Hinton agar plates and disks containing
30 μg ceftazidime (with and without 10 μg clavulanic
acid) and 10 μg imipenem (with and without 750 μg
EDTA) were placed on the surface of the media. The
plates were incubated at 37°C overnight. P. aeruginosa
NCTC 10662, E. coli NCTC 10418, and S. aureus NCTC
6571 were used as controls on every plate.Identification of resistance genes
The presence of resistant genes listed below was investi-
gated by PCR assays. PCR was conducted in a GeneAmp
9700 (Perkin-Elmer, Waltham Massachusetts, USA) sys-
tem using the conditions specified for each primer; cor-
responding to the source references. blaTEM-1& blaSHV,
blaCTX-M-like [9], bla NDM [13], blaOXA-1 [3], qnrA and
qnrS [29], qnrB [30], aac(6’)-Ib Ib-cr [31], gyrA & parC
[32], gyrB & parE [33]; intI1 [34] & intI2 [35], blaVIM,
blaIMP, blaOXA-48 [19], ampC [8], IS [36].Table 1 The distribution of 832 isolates by hospital, year, and
recovered
Hospital Total Year Urine Blood Wound Gastric Fluid Ca
Amiri (ADA) 240 2010
2011 49 1 2
2012 177 5 1
Ahmadi (KOC) 236 2010 87 7 13 2 8
2011 48 1
2012 51 2 1
Yiaco-Adan (Y) 356 2010
2011
2012 305 13 24 1 2Amplified PCR products were purified with Qiagen
purification kit (Qiagen Valencia, CA, USA) according to
the manufacturer’s instructions and both strands were se-
quenced by automated AB13100 DNA sequencer (Applied
Biosystems, Carlsbad, CA, USA) system. The BLAST pro-
gram of the National Centre for Biotechnology Informa-
tion (http://www.ncbi.nlm.nih.gov) was used to search and
compare databases for similar nucleotide acid sequences.
Pulsed-field gel electrophoresis
Pulsed-Field Gel Electrophoresis (PFGE) analysis was
based on techniques described elsewhere [37]. After
PFGE, the gels were stained with ethidium bromide and
scanned. The analysis of the gels was performed using
BioNumerics software version 7.1 (Applied Maths, Ghent,
Belgium). This software facilitates the development of the
algorithms necessary for the comparison of profiles of
isolates based on the Dice coefficient and the hierarchic
unweighted pair arithmetic average algorithm. Cluster
analysis and phylogenetic trees were subsequently ana-
lysed with an optimization of 1.0% and a tolerance of
0.7%. Isolates were considered to belong to the same
PFGE clone if their Dice similarity index was ≥85%.
Plasmid analysis
Plasmids were extracted (Promega, Fitchburg, WI, USA)
and characterized by PCR as described previously [38].
Plasmids from clinical isolates were detected using
PFGE. A single block was incubated at 55°C for 1 hour
with 1 unit of S1 nuclease (New England Biolabs, Ips-
wich, MA, USA) in Zinc Buffer (200 μl of 50 mM NaCl,
30 mM sodium acetate and 5 mM ZnSO4). Electrophor-
esis was performed at 6 V, 5-50s for 20 h [39].
Resistance transfer assays
Mating experiments were performed with E. coli J62-2
(RifR) as the recipient strain. Cultures of the donor
(KOC-10 harbouring blaCTX-M-56, qnrB1 and blaCMY-2
genes) and the recipient strain were grown in Luria-sample from which the isolates were originally
theter tip Ascetic Fluid Eye Pleural Fluid Sputum Tissue Pus





Table 2 The distribution of 83 isolates by hospital, year, and sample from which the isolates were originally recovered
Hospital Total no. Year Urine Blood Wound Pus Catheter tip Ascetic Fluid Eye Pleural Fluid Sputum
Amiri (ADA) 9 2010
2011 1
2012 8
Ahamdi (KOC) 57 2010 38 5 2 2 2 1
2011 3
2012 3 1
Yiaco-Adan (Y) 17 2010
2011
2012 13 2 1 1
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1:4 and incubated for 5 hours at 37°C. Transconjugates
(0.1 ml) were selected on LB agar plates containing ri-
fampicin (150 mg/L) and cefotaxime (2 mg/L). The
transconjugates were tested for antibiotic resistance
followed by PCR of the resistance determinants.
Result
Bacterial isolates and the detection of O25b-ST131
All three hospitals participated during our study period;
however there were inconsistencies in the level of strain
contribution for each year. Therefore under-representation
of E. coli multi-drug resistant isolates might exist. We
tested a subset of 832 E. coli MDR (Table 1). Of which
83 (10%) were identified as the O25b-sequence type
(ST) 131 clone of B2 phylogenic group. The principal
source of isolation (81%) was urine; mainly from pa-
tients older than 60 years of age, these comprised 49%
of all the urine specimens. The distribution of these 83
isolates and the source of isolation are presented in
Table 2. (Also see Additional file 1).
PCR amplification and sequencing
Table 3 shows the distribution of the bla genes among
the 83 isolates of E. coli O25b-ST131. Four (4.8%) didTable 3 Molecular characterization of bla genes among E.
coli O25b-B2-ST131in Kuwait
Profiles of the antibiotic resistance genes No. of isolates (%)
bla TEM-1 2 (2.4)
bla SHV-12 1 (1.2)
bla CTX-M-2 1 (1.2)
bla CTX-M-15 32 (38.6)
bla CTX-M-56 1 (1.2)
bla TEM-1, bla SHV-12 1 (1.2)
bla CTX-M-15, bla SHV-12 9 (10.8)
bla CTX-M-15, bla TEM-1 21 (25.3)
bla CTX-M-15, bla TEM-1, bla SHV-12 12 (14.5)not contain any of the β-lactamase enzymes while the
majority (95.2%) harboured at least one β-lactamase re-
sistance gene. Two isolates harboured blaCTX-M-2 and
blaCTX-M-56. blaNDM, blaIMP and blaVIM genes were not
found. ISEcp1 was detected upstream region of 25 (33%)
of the blaCTX-M-15 positive isolates. blaCMY-2 was only
detected in four isolates (4.8%). IS elements were de-
tected in 2 blaCMY-2 positive isolates, 1 contained class 1
integrons and 1 class II integrons.
Class 1 integrons were identified in 30 (36.1%) isolates
and only 5 (6%) contained class II integrons. None of
the isolates contained both classes of integrons.
Quinolone resistance determinants
All but two isolates were resistant or had intermediate
resistance to ciprofloxacin (MIC > 2 mg/l). Two sensitive
isolates did not contain aac(6’)-Ib Ib-cr (isolates Y-116
and Y-159). We did not detect qnrA gene in any of the
isolates tested. Three isolates harboured qnrB1 and 4
harboured qnrS1. qnrB1 and qnrS1 coexisted in only 2
isolates (Table 4).
Fifty six (67.5%) isolates carried aac(6’)-Ib Ib-cr.
Among the aac(6’)-Ib Ib-cr negative strains (27/83)
32.5%, 1 isolate carried qnrB1 and blaCTX-M-56 (KOC-10)
and 1 isolate carried qnrS1 (ADA-234). The remaining
78% (7/9) qnr positive isolates also contained aac(6’)-IbTable 4 The profile of quinolone resistant E. coli O25b-
B2-ST131isolates
Profiles of the antibiotic resistance genes No. of
Isolates
bla CTX-M-56, blacmy-2, qnrB1 1
bla CTX-M-15, aac(6’)-Ib-cr, bla TEM-1, qnrB1 1
bla CTX-M-15, aac(6’)-Ib-cr, bla OXA-1, bla TEM-1, qnrB1, ISEcp1 1
bla CTX-M-15, aac(6’)-Ib-cr, bla OXA-1,, bla TEM-1, qnrS1, ISEcp1 1
bla CTX-M-15, aac(6’)-Ib-cr, bla OXA-1,, qnrB1, qnrS1 2
bla CTX-M-15, aac(6’)-Ib-cr, bla OXA-1,, qnrS1, ISEcp1 2
bla CTX-M-15, qnrS1, bla OXA-1,, ISEcp1 1
Total 9
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blaSHV.
No mutations were detected in the quinolone-resistance-
determining regions of gyrA. However, there was a new
mutation in isolate D-140 topoisomerase subunit IV
at position 520 G to C that altered 174 Val (GTC) to
Leu (CTC) possibly not leading to any additional
chromosome encoded fluoroquinolone resistance. We
also observed mutations in isolate Y-190 in topoisomer-
ase subunit IV; the amino acid 560A→ V and at pos-
ition 840 V→A.
PFGE
PFGE showed diverse genetic profiles (Figure 2). The
isolates that harboured qnr genes; although resemble
similar phenotypes; some displayed unrelated PFGE
profiles suggesting that they were not epidemic cases
(Figure 1). The genotyping results of the 5 isolates that
contained class II integrons suggested that only two of
these isolates have identical PF patterns and harboured
similar antibiotic resistant profiles whereas the other
three isolates were not closely related and contained dif-
ferent resistance genes including one isolate which con-
tained the AmpC gene blaCMY-2. All 5 harboured
blaCTX-M-15 (Figure 3).
Antimicrobial susceptibility
We identified 3 (3.6%) of the E. coli O131 isolates did
not contain β-lactam resistance genes which reflect the
infection caused by cephalosporin-susceptible clones
(KOC-3, KOC-47 and Y-136). These isolates were col-
lected from two different hospitals, all from urine speci-
mens and were not related by PFGE to each other but
were closely related to other isolates that contained
blaCTX-M-15 (Figure 2).
Plasmid analysis
IncFII plasmid that also contains β-lactamase gene blaOXA-1
that encodes for OXA-1 and the aminoglycoside/
fluoroquinolone acetyl transferase aac(6’)-Ib-cr was






























































Figure 1 PFGE profiles of E. coli O25b-B2-ST131isolates collected in th
the scale at the top left of the figure. Isolate no. Specimen Age Gender.contained both genes. The isolate (KOC10) harbouring
blaCTX-M-56 gene also contained qnrB1 and blaCMY-2
genes and carried IncF1 plasmids of about 97 kb and
160 kb (Figure 4). Number of transconjugants in 1 ml
for KOC10 was on average 40 to 6 × 102 which com-
prised of 4 × 10−8 to 6 × 10−7 transconjugants per donor
cell. PCR revealed that only one of the transconjugates
contained qnrB1 and blaCMY-2 genes and one contained
qnrB1 and blaCTX-M-56.
Discussion
This manuscript reports the trend of E. coli O25b-ST131
isolated non-selectively in hospitals. During our two year
study 10% of MDR E. coli isolated belonged to the E. coli
O25b-ST131 clonal group indicating that the Middle
East has joined the countries affected by this virulent
pathogen posing a major public health concern. MDR
E. coli O25b-ST131isolates were isolated from different
age groups of patients (3-94 years old; with the average
age of 54.4 years old).
The majority of isolates (38.6%) harboured only
blaCTX-M-15 and 10.8% also contained blaTEM and or
blaSHV. Among ESBL producers; we detected the pres-
ence of blaCTX-M-56 for the first time in the Middle East
and outside the South American continent [40]. The pa-
tient from which the isolate was recovered had an inter-
national travel history to an endemic region. Also we
detected blaCTX-M-2, one of the dominant Asian β-
lactamases [41] for the first time in the Middle East.
blaCTX-M-56 gene is in the same context as blaCTX-M-2 by
a single nucleotide mutation (G824A), resulting in a re-
placement of serine by asparagine at position 275 [42].
Previously no explanation was given as to what this
change means, however we propose that based on other
class A β-lactamases [43,44], as this modification takes
place at the C terminal of the α-11 helix it is involved in
the resistance to inactivation by β-lactamase inhibitors.
The isolate harbouring blaCTX-M-56 also contained qnrB1
and blaCMY-2 genes and carried IncF1 plasmids of about
97 kb and160 kb. Production of plasmid AmpC such




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2 Relationship between banding patterns after digestion with XbaI endonuclease enzyme showing the percentage similarity
between group types and clusters for 83 E. coli O25b-B2-ST131 isolates using DICE/UPGMA with an optimization of 1.0% and a
tolerance of 0.5% generated by BioNumerics software (v.7.1).
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hibitors. Therefore the emergence of a clinical isolate
that contains blaCMY-2 as well as blaCTX-M-56 poses a risk
to combination β-lactam/ β-lactamase inhibitor therapy.We also detected the presence of qnr genes in eight
other blaCTX-M-15 harbouring isolates. Although Qnr en-
zyme by itself produces low-level resistance to quino-































































































Figure 3 PFGE profiles of E. coli O25b-B2-ST131isolates containing Class II integron.
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in resistance to quinolones.
ISEcp1-blaCTX-M-15 element was located in the up-
stream region of 33% of isolates harbouring blaCTX-M-15.
Twenty seven per cent of which were associated with
blaSHV, blaTEM as well as blaCTX-M-15. ISEcp1 plays a






Figure 4 Agarose gel showing S1 nuclease PFGE-based sizing
of large plasmids from E. coli O25b-B2-ST131
harbouring blaCTX-M-56.β-lactamase genes and supports their dissemination [45].
IncFII plasmid that also harboured blaOXA-1 and the
aminoglycoside/fluoroquinolone acetyl transferase aac
(6’)-Ib-cr gene (aac(6’)-Ib Ib-cr) was present in 59 (71%)
of isolates of which 33 (40%) contained both genes. Two
isolates containing blaOXA-48 contained ISEcp1 and class
1 integrons. It has been reported [46] that a novel
Tn1999 transposon inserted into a single 62-kb IncL/
M-type plasmid is responsible for the dissemination of
blaOXA-48 gene in E. coli strains.
The rate of carriage of MDR E. coli O25b-ST131 is es-
timated at 7% in healthy adults [47]; however the rate of
E. coli O25b-ST131 susceptible to extended-spectrum
cephalosporins has never been reported. We identified
3.6% of the E. coli O131 isolates did not contain any of
the related resistance genes which reflect the infection
caused by cephalosporin-susceptible clones.Conclusion
We did not find any association between resistance pro-
files and genotypes. However; we detected for the first
time the appearance blaCTX-M-2 in the Middle East and
blaCTX-M-56 outside Latin America. We also identified the
spread of qnrB1 and qnrS1 in isolates harbouring aac(6’)-
Ib Ib-cr and blaCTX-M. The isolate harbouring blaCTX-M-56
also contained qnrB1 and blaCMY-2 genes and carried
IncF1 plasmids. In conclusion the appearance of a highly
virulent E. coli O25b-ST131 that is resistant to penicillins,
most cephalosproins, β-lactamase inhibitors as well as
floroquinolones is a cause for concern and poses a risk to
combination β-lactam/ β-lactamase inhibitor therapy.Additional file
Additional file 1: Table S1. Specimen types and Demographics of
E. coli O25b-B2-ST131 isolates. Samples from pus, skin and wound have
been illustrated under soft tissue.Competing interests
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